Structural Biology Program

The Dinshaw Patel Lab


Pictured: Dinshaw Patel
Dinshaw Patel, PhD


Our group applies structural (cryo-EM, x-ray crystallography and NMR), biochemical and biophysical methods together with functional studies to investigate macromolecular-mediated recognition, regulation and catalysis. The ongoing major projects in the laboratory focus on the structural biology of CRISPR-Cas surveillance complexes and their suppression by anti-CRISPR proteins (in collaboration with Luciano Marraffini, Rockefeller), on Structure Maintenance of Chromosome Smc5/6 (with Xiaolan Zhao, MSKCC) and MRX (with John Petrini, MSKCC) complexes involved in double-strand break and stalled replication fork repair, and on complexes mediating the meiotic recombination pathway (with Scott Keeney, MSKCC). In addition, research is focused on protein-RNA complexes mediating the piRNA pathway (with Julius Brennecke, IMBA-Austria), on identification and characterization of small molecule inhibitors targeted to proteins of the cGAS-STING pathway and the SARS-CoV-2 family (with Thomas Tuschl, Rockefeller) and those that impact on proteins triggering the onset of acute myeloid leukemia (with Michael Kharas, MSKCC).

Our group retains an interest in the areas of structure-function studies of RNA interference mediated by siRNA pathway, and on post-translation histone and DNA modifications impacting on epigenetic regulation. Additional areas include RNA-mediated events ranging from cofactor recognition by riboswitches, catalysis by ribozymes and protein-RNA recognition events impacting on disease syndromes and the principles underlying the molecular basis of glycosphingolipid and phospholipid binding specificity by lipid transfer proteins.


Meeske, A. J., Jia, N., Cassel, A., Kozlova, A., Liao, J., Wiedman, M., Patel, D. J. & Marraffini, L. A. (2020). Phage-encoded anti-CRISPR enables full escape from type VIA CRISPR-Cas immunity. Science 369, 54-59.

Li, W., et al., Gozani, O., Patel, D. J. & Wang, Z. (2021). Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases. Nature 590, 498-503.

Rostol, J.T., Xie, W., Kuryavyi, V., Kao, K., Fromm, R., Patel, D. J. & Marraffini, L. A. (2021). The Card1 nuclease provides bacterial defense during Type III CRISPR immunity. Nature 590, 624-629.

Wang, J., Catania, S., Wang, C., de la Cruz, M. J., Rao, B., Madhani, H. & Patel, D. J. (2022). SNF2 ATPase remodels DNA methyltransferase to enable durable epigenetic memory. Mol. Cell 82, 1186-1198.

Yu, Y., Li, S., Ser, Z., Kuang, H., Than, T., Guan, D., Zhao, X. & Patel, D. J. Cryo-EM structure of DNA-bound Smc5/6 reveals DNA clamping enabled multi-subunit conformational changes. Proc. Natl. Acad. Scis. USA in press.


All Publications >


View Lab Overview

Research Projects


Pictured: Dinshaw Patel

Dinshaw Patel, PhD


  • The Patel laboratory studies the structural biology of macromolecular recognition, regulation and catalysis. Ongoing projects include structure-function studies of the CRISPR-Cas and cGAS-STING surveillance pathways, on the role of Structure Maintenance Chromosome complexes in mediating DNA double strand break repair, on the role of histone and DNA methylation in epigenetic regulation and on RNA-mediated processes ranging from riboswitches and ribozymes to those governing siRNA and piRNA pathways.
  • PhD, New York University
[email protected]
Email Address
Office Phone
Download CV
PDF File


Marianna Teplova
Marianna Teplova

Senior Research Scientist

Malbelyn Fraticelli


Vitaly V. Kuryavyi
Vitaly V. Kuryavyi

Senior Research Scientist

Puja Majumder

Research Scholar

You Yu, PhD
You Yu

Research Associate

Lab Affiliations


  • Jamshetjee N. Tata Fellow (1961-1963)
  • AT&T Bell Laboratories Distinguished Technical Staff Award (1983)
  • Abby Rockefeller Mauzé Chair in Experimental Therapeutics, MSKCC (1992-current)
  • Distinguished Alumnus Award, New York University (1997)
  • Harvey Society, President (1998-1999)
Read more
  • Member, National Academy of Sciences, USA (2009)
  • NIH Directors Transformative Research Grant with Thomas Tuschl and Uwe Ohler (2013)
  • Member, American Academy of Arts and Sciences, USA (2014)
  • FEZANA Jamshed and Shirin Guzdar Excellence in Profession Award (2014)
  • Einstein Professorship of Chinese Academy of Sciences, China (2015)
  • Lifetime Achievement Award, American Association of Indian Scientists in Cancer Research (2019)
  • Inaugural Tan Jiazhen International Life Science Collaboration Award (2019)

Get in Touch


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Dinshaw Patel discloses the following relationships and financial interests:

  • Ankrin Therapeutics
    Intellectual Property Rights
  • Chinese Academy of Sciences
    Provision of Services
  • Chinook Therapeutics
    Intellectual Property Rights
  • Harbin Institute of Technology, Harbon, China
    Provision of Services
  • Institute Research Biomedicine, Barcelona, Spain
    Provision of Services
  • Southern University of Science and Technology
    Provision of Services (uncompensated)
  • Takeda Pharmaceuticals
    Intellectual Property Rights
  • Tsinghua University
    Provision of Services (uncompensated)
  • Ventus Therapeutics
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures